Zhejiang Biopharma Dark Horse Sees Minor Stake Reduction by Investor, Shares Dip by Approximately 0.3%

Pencil News, September 5th: According to data from the Enterprise Early Warning System, the investment ratio of SDIC (Shanghai) Technology Achievement Transformation Venture Capital Fund Enterprise (Limited Partnership) ("SDIC Shanghai Fund") in Zhejiang Haichang Biotech Co., Ltd. ("Haichang Biotech") has slightly decreased.

After this change, the investment amount of SDIC Shanghai Fund is RMB 2.55268 million, and the investment ratio has decreased from 8.5763% to 8.2675%, with a decrease of 0.3088%.

SDIC Shanghai Fund, as an investment fund focused on the transformation of scientific and technological achievements, prioritizes supporting technological innovation and industrial upgrading, particularly in high-tech industries such as biomedicine, new materials, and new energy. Through equity investment and capital operations, the fund is committed to promoting the commercialization and industrialization of scientific and technological achievements, accelerating the growth of technology-driven enterprises.

The invested party, Haichang Biotech, located in China Medical Valley, Hangzhou, is a national high-tech enterprise mainly engaged in the innovative development of biopharmaceutical technologies, with independent innovation capabilities and a global intellectual property layout.

The company focuses on the development of innovative nucleic acid drugs such as small nucleic acid drugs, mRNA vaccines, and complex injectables.

Currently, albumin paclitaxel has been approved for marketing in China and the EU, with registration applications ongoing in multiple countries along the Belt and Road. HC0301, a novel Class I small nucleic acid drug, has received dual approval from the FDA and NMPA and is currently undergoing global multi-center Phase II clinical trials. The mRNA COVID-19 vaccine booster has been approved by the FDA for clinical trials, making it the first Chinese-produced mRNA vaccine product to receive U.S. clinical approval. The product pipeline covers areas such as infectious disease prevention, tumor immunotherapy, anti-tumor treatments, and pain management.

Since its establishment, the company has been committed to developing innovative biopharmaceutical products to meet the market's demand for high-quality pharmaceuticals. Haichang Biotech possesses multiple patented technologies in the biopharmaceutical field and has established cooperative relationships with several medical institutions and scientific research institutes.